A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (NCT07332481)
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-1)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Who can join: Review the eligibility criteria below.
Location: Dermatology Research Associates - 300204025 — Los Angeles, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Dermatology Research Associates - 300204025 — Los Angeles, California
- Cohen Medical Centers — Thousand Oaks, California
- GNP Research at Mark Jaffe, MD — Cooper City, Florida
- Advance Medical Research Center — Miami, Florida
- Diverse Clinical Research LLC — Miami, Florida
- D&H National Research Centers, Inc. — Tamarac, Florida
- Clinical Research of West Florida, Inc. — Tampa, Florida
- Emory University School of Medicine — Atlanta, Georgia
- Revival Research Institute, LLC — Troy, Michigan
- Allen Arthritis — Allen, Texas
- Arthritis and Rheumatology Research Institute PLLC — Allen, Texas
- Arthritis Care of Texas — Corpus Christi, Texas
- JCHO Chukyo Hospital - Dept of Dermatology — Nagoya, Aichi-ken
- NHO Chibahigashi National Hospital - Dept of Allergy/Rheumatology — Chiba, Chiba
- Sapporo City General Hospital - Dept of Rheumatology/Immunology — Sapporo, Hokkaido
- Kanazawa University Hospital - Dept of Rheumatology/Immunology — Kanazawa, Ishikawa-ken
- St. Luke's International Hospital - Dept of Immunology/Allergy — Chūōku, Tokyo-To
- Kantonsspital St. Gallen - Klinik f. Dermatologie, Venerologie u Allergologie — Sankt Gallen,
📞 Contact the Study Coordinator
Phone: +49 6151 72 5200
Email: service@emdgroup.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus (SLE)
- Descartes-08 for Patients With Systemic Lupus Erythematosus — Oceanside, California
- A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Farmington, Connecticut
- Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — Bethesda, Maryland
- A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants — Mesa, Arizona
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires — Bethesda, Maryland
Explore by condition: All Systemic Lupus Erythematosus (SLE) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.